HABP/VABP Regimens
FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICU

Released: December 06, 2022

Expiration: December 05, 2023

Marion Elligsen
Marion Elligsen, BScPhm, MSc, RPh, ACPR
Keith S. Kaye
Keith S. Kaye, MD, MPH
Andrew Shorr
Andrew Shorr, MD, MPH, MBA

Activity

Progress
1
Course Completed

In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including:

  • The role of novel β-lactam/β-lactamase inhibitor combinations
  • Use of clinical predictions scores (eg, Drug Resistance in Pneumonia DRIP score) to predict risk for pneumonia caused by multidrug-resistant pathogens
  • Application of rapid diagnostic testing in critically ill patients with pneumonia, including current limitations
  • Implementation of advanced antibiograms and clinical prediction scores
  • Clinical utility of biomarkers for pneumonia (eg, procalcitonin)
  • Application of updated nosocomial pneumonia classifications in clinical practice